IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc.

IDXX

NASDAQHealthcareMedical - Diagnostics & Research

Previous close

$556.93

+$11.07 · +2.03%

Aug 21, 4:00 PM ET

Pre-market

$555.99

−$0.94 · -0.17%

Aug 24, 7:00 AM ET

IDXX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

42

Neutral

Sentiment

68

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Michael Erickson
Listed since
Jun 21, 1991
Employees
11,000

Market position

Day range

Current $556.93

52-week range

Current $556.93

Open
$546.4
Previous close
$545.86
Volume
485.78K
0.76× average
Average volume
639.12K
Average daily volume
Market cap
43.93B USD
Beta
1.54
Market reference 1
50-day average
$560
-0.55% below average
200-day average
$615.1
-9.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
55.08B USD
P/E (TTM)
39.11×
P/B (TTM)
27.66×
P/S (TTM)
9.65×
EV / EBITDA
37.5×
Earnings yield
1.96%
Free cash flow yield
1.94%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.45%
Operating margin
32.03%
Net margin
25.03%
Return on equity
65.99%
Return on assets
31.62%
Return on invested capital
40.27%

Financial health

Debt / equity
0.68×
Current ratio
1.17×

Earnings

Latest fiscal-year EPS
13.08
FY2025 · +22.59% year over year
Latest fiscal-year revenue
4.3B USD
FY2025 · +10.42% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend13.5911.579.557.52FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend4.41B3.98B3.54B3.11BFY21FY22FY23FY24FY25

IDXX news

IDXX peers

ETFs holding IDXX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research IDXX

research.disclaimer